Ribas A - Search Results

1

Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy.

Bellmunt J, Albanell J, Gallego OS, Ribas A, Vicente P, Carulla J, De Torres J, Morote J, Lopez M, Solé LA. Bellmunt J, et al. Among authors: ribas a. Cancer. 1992 Oct 1;70(7):1974-9. doi: 10.1002/1097-0142(19921001)70:7<1974::aid-cncr2820700727>3.0.co;2-d. Cancer. 1992. PMID: 1525774 Clinical Trial.

2

Phase II trial of an all-oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancer.

Solé LA, Albanell J, Bellmunt J, Ribas A, Gallego OS, Carulla J. Solé LA, et al. Among authors: ribas a. Cancer. 1995 Feb 1;75(3):831-5. doi: 10.1002/1097-0142(19950201)75:3<831::aid-cncr2820750314>3.0.co;2-s. Cancer. 1995. PMID: 7828134 Clinical Trial.

3

[Gene therapy: new prospects in the treatment of cancer].

Ribas A, Bellmunt J. Ribas A, et al. Med Clin (Barc). 1994 Dec 10;103(20):776-9. Med Clin (Barc). 1994. PMID: 7861836 Spanish. No abstract available.

4

Malignant lymphoproliferative diseases in HIV-seropositive patients. A study of 40 cases at a single institution in Spain.

Ribas A, Bellmunt J, Albanell J, Capdevila JA, Ocaña I, Gallego OS, Maldonado J, Giralt J, Solé LA. Ribas A, et al. Acta Oncol. 1995;34(1):75-82. doi: 10.3109/02841869509093642. Acta Oncol. 1995. PMID: 7865239 Clinical Trial.

5

[Initial clinicopathological manifestations of malignant lymphoproliferative processes in patients with human immunodeficiency virus seropositivity. Study of 40 cases].

Bellmunt J, Ribas A, Ocaña I, Capdevila JA, Ruiz-Marcellan MC, Giralt J, Sole LA. Bellmunt J, et al. Among authors: ribas a. An Med Interna. 1994 May;11(5):217-23. An Med Interna. 1994. PMID: 8061135 Spanish.

6

[Corticoid treatment in Castleman's disease].

Ribas A, Bellmunt J, Solé LA, Ribas-Mundó M. Ribas A, et al. Among authors: ribas mundo m. Med Clin (Barc). 1995 Nov 11;105(16):638-9. Med Clin (Barc). 1995. PMID: 8523950 Spanish. No abstract available.

7

Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity.

Ribas A, Albanell J, Bellmunt J, Solé-Calvo LA, Bermejo B, Gallardo E, Vidal R, Vera R, Eres N, Carulla J, Baselga J. Ribas A, et al. J Clin Oncol. 1996 May;14(5):1573-80. doi: 10.1200/JCO.1996.14.5.1573. J Clin Oncol. 1996. PMID: 8622074 Clinical Trial.

8

M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladder.

Bellmunt J, Ribas A, Albanell J, Bermejo B, Vera R, De Torres JA, Morote J, Lopez-Pacios MA, Banus JM, Rovirosa A, Carulla J, Sole LA. Bellmunt J, et al. Among authors: ribas a. Am J Clin Oncol. 1996 Aug;19(4):344-8. doi: 10.1097/00000421-199608000-00004. Am J Clin Oncol. 1996. PMID: 8677901 Clinical Trial.

9

Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis.

Albanell J, Bellmunt J, Molina R, García M, Caragol I, Bermejo B, Ribas A, Carulla J, Gallego OS, Español T, Solé Calvo LA. Albanell J, et al. Among authors: ribas a. Anticancer Res. 1996 Mar-Apr;16(2):1027-32. Anticancer Res. 1996. PMID: 8687094

10

[Preliminary results of a phase II randomized controlled trial comparing M-VAC and M-CAVI in patients with bladder cancer (T2-4 N0-1 M0)].

Bellmunt Molins J, Ribas A, Albanell J, Lorente Garín JA, de Torres Mateos JA, Morote Robles J, López Palacios MA, Banús Gassol JM, Casado Cobo S, Eres N, Solé Calvo LA. Bellmunt Molins J, et al. Among authors: ribas a. Arch Esp Urol. 1996 Jun;49(5):465-72. Arch Esp Urol. 1996. PMID: 8766083 Clinical Trial. Spanish.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

720 results

Search Page